Protein S modulates the anticoagulant action of recombinant human activated protein C: A comparison between neonates and adults

British Journal of Pharmacology

Volumn 146, Issue 8, 2005, Pages 1082-1086

  Cvirn, Gerhard ^a   Koestenberger, Martin ^a   Leschnik, Bettina ^a   Male, Christoph ^b   Kutschera, Joerg ^a   Ferstl, Ulrika ^a   Muntean, Wolfgang ^a   Juergens, Guenther ^a   Gallistl, Siegfried ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cord and adult plasma; Protein S; Recombinant human activated protein C; Sepsis; Thrombin generation

Indexed keywords

ANTITHROMBIN; DROTRECOGIN; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGE DISTRIBUTION; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; NEWBORN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FETAL BLOOD; HUMANS; INFANT, NEWBORN; PLASMA; PROTEIN C; PROTEIN S; RECOMBINANT PROTEINS;

EID: 28944440685     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706436     Document Type: Article

References (29)

1. ANDREW, M., PAES, B., MILNER, R., JOHNSTON, M., MITCHELL, L., TOLLEFSEN, D.M. & POWERS, P. (1987). Development of the human coagulation system in the full-term infant. Blood, 70, 165-172.
2. BARTON, P., KALIL, A.C., NADEL, S., GOLDSTEIN, B., OKHUYSEN-CAWLEY, R., BRILLI, R.J., TAKANO, J.S., MARTIN, L.D., QUINT, P., YEH, T.S., DALTON, H.J., GESSOURON, M.R., BROWN, K.E., BETTS, H., LEVIN, M., MACIAS, W.L., SMALL, D.S., WYSS, V.L., BATES, B.M., UTTERBACK, B.G. & GIROIR, B.P. (2004). Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics, 113, 7-17.
3. BERNARD, G.R., VINCENT, J.L., LATERRE, P.E., LAROSA, S.P., DHAINAUT, I.E., LOPEZ-RODRIGUEZ, A., STEINGRUG, J.S., GARBER, G.E., HELTERBRAND, J.D., ELY, E.W. & FISHER JR, C.J. (2001). Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 344, 699-709.
4. BUTENAS, S., VAN'T VEER, C. & MANN, K.G. (1999). 'Normal' thrombin generation. Blood, 94, 2169-2178.
5. CVIRN, G., GALLISTL, S., KOESTENBERGER, M., BAIER, K., FRITSCH, P., GREILBERGER, J., JUERGENS, G. & MUNTEAN, W. (2004). The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin alpha activated): comparison between cord and adult plasma. Thromb. Haemost., 91, 912-918.
6. CVIRN, G., GALLISTL, S., KÖSTENBERGER, M., KUTSCHERA, J., LESCHNIK, B. & MUNTEAN, W. (2002). Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb. Res., 105, 433-439.
7. CVIRN, G., GALLISTL, S., LESCHNIK, B. & MUNTEAN, W. (2003a). Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in the neonate. J. Thromb. Haemost., 1, 263-268.
8. CVIRN, G., GALLISTL, S., REHAK, T., JÜRGENS, G. & MUNTEAN, W. (2003b). Elevated thrombin-forming capacity of tissue factor-activated cord compared with adult plasma. J. Thromb. Haemost., 1, 1785-1790.
9. DAHLBÄCK, B. (1991). Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb. Haemost., 66, 49-61.
10. DAHLBÄCK, B. & VILLOUTREIX, B.O. (2003). Molecular recognition in the protein C anticoagulant pathway. J. Thromb. Haemost., 1, 1525-1534.
11. DAVIE, E.W., FUJIKAWA, K. & KISIEL, W. (1991). The coagulation cascade: initiation, maintenance and regulation. Biochemistry, 30, 10363-10370.
12. DHAINAUT, J.F., YAN, S.B., JOYCE, D.E., PETTILA, V., BASSON, B., BRANDT, J.T., SUNDIN, D.P. & LEVI, M. (2004). Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J. Thromb. Haemost., 2, 1924-1933.
13. FOURRIER, F. (2004). Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review. Crit. Care. Med., 32, S534-S541.
14. FULCHER, C.A., GARDINER, J.E., GRIFFIN, J.H. & ZIMMERMANN, T.S. (1984). Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood, 63, 486-489.
15. HEEB, M.J., KOENEN, R.R., FERNANDEZ, J.A. & HACKENG, T.M. (2004). Direct anticoagulant activity of protein S-C4b binding protein complex in Heerlen heterozygotes and normals. J. Thromb. Haemost., 2, 1766-1773.
16. HEMKER, H.C., WIELDERS, S., KESSELS, H. & BEGUIN, S. (1993). Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb. Haemost., 70, 617-624.
17. HEMKER, H.C., WILLEMS, G.M. & BEGUIN, S. (1986). A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb. Haemost., 56, 9-17.
18. KUHLE, S., MALE, C. & MITCHELL, L. (2003). Developmental hemostasis: pro- and anticoagulant systems during childhood. Semin. Thromb. Hemost., 29, 329-337.
19. LORENTE, J.A., GARCIA-FRADE, L.J., LANDIN, L., DE PABLO, R., TORRADO, C., RENES, E. & GARCIA-AVELLO, A. (1993). Time course of hemostatic abnormabilities in sepsis and its relation to outcome. Chest, 103, 1536-1542.
20. MANN, K.G., BRUMMEL, K. & BUTENAS, S. (2003). What is all that thrombin for? J. Thromb. Haemost., 1, 1504-1514.
21. MARTINEZ, M.A., PENA, J.M., FERNANDEZ, A., JIMENEZ, M., JUAREZ, S., MADERO, R. & VAZQUEZ, J.J. (1999). Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha. Crit. Care Med., 27, 1303-1308.
22. MARTINOT, A., LECLERC, F., CREMER, R., LETEURTRE, S., FOURIER, C. & HUE, V. (1997). Sepsis in neonates and children: definitions, epidemiology, and outcome. Pediatr. Emerg. Care, 13, 277-281.
23. PETÄJÄ, J. & MANCO-JOHNSON, M.J. (2003). Protein C pathway in infants and children. Semin. Thromb. Hemost., 29, 349-361.
24. RAWICZ, M., SITKOWSKA, B., RUDZINSKA, I., KORNACKA, M. & BOCHENSKI, P. (2002). Recombinant human activated protein C for severe sepsis in a neonate. Med. Sci. Monit., 8, CS90-CS94.
25. RIJKERS, D.T., WIELDERS, S.J., BEGUIN, S. & HEMKER, H.C. (1998). Prevention of the influence of fibrin and alpha 2-macroglobulin in the continuous measurement of the thrombin potential: implications for an endpoint determination of the optical density. Thromb. Res., 89, 161-169.
26. SCHWARZ, H.P., MUNTEAN, W., WATZKE, H., RICHTER, B. & GRIFFIN, J.H. (1988). Low total protein S antigen but high protein S activity due to decreased C4b-binding protein in neonates. Blood, 71, 562-565.
27. SORENSEN, B., JOHANSEN, P., CHRISTIANSEN, K., WOELKE, M. & INGERSLEV, J. (2003). Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J. Thromb. Haemost., 1, 551-558.
28. VAN'T VEER, C., GOLDEN, N.J., KALAFATIS, M. & MANN, K.G. (1997). Inhibitory mechanism of the protein C pathway on tissue factor-activated thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J. Biol. Chem., 272, 7983-7994.
29. WIELDERS, S., MUKHERJEE, M., MICHIELS, J., RIJKERS, D.T., CAMBUS, J.P., KNEBEL, R.W., KAKKAR, V., HEMKER, H.C. & BEGUIN, S. (1997). The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb. Haemost., 77, 629-636.